Overall rank by patents
#19,252
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Taiwan Redeye Biomedical Inc.
USPTO PatentsView assignee record - 15 granted patents across 12 technology areas, active 2020–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).
15
Total patents granted
12
CPC technology areas
13.8
Avg claims per patent
-
5-year filing velocity
The verdict
Taiwan holds 15 US patents across 12 technology areas, rank #19,252 of 50,000 tracked assignees.
- #19,252
- of 50,000 US assignees by volume
- Top 17%
- by Innovation Score (48.4/100)
- 13.8
- avg claims per patent
Portfolio overview
Taiwan Redeye Biomedical Inc. has been granted 15 US utility patents between 2020 and 2024, placing Taiwan Redeye Biomedical Inc. at rank #19,252 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.8 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a Foreign Corporation, Taiwan Redeye Biomedical Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 48.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2024, with 15 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Taiwan Redeye Biomedical Inc.'s 13.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Taiwan Redeye Biomedical Inc. against peers pursuing similar technology classes.
How does Taiwan compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Taiwan Redeye Bio… ◀ 15
Taiwan RedEye Biomedical Inc.
15 patents
What this shows Taiwan holds 15 patents, placing it at rank #19,252 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Taiwan's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 17% higher than 83% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2020–2024
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 3 | 20.0% |
| 2021 | 1 | 6.7% |
| 2022 | 3 | 20.0% |
| 2023 | 3 | 20.0% |
| 2024 | 5 | 33.3% |
Which technologies does Taiwan Redeye Biomedical Inc. patent most?
Top 12 of 12 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Frequently Asked Questions
How many patents does Taiwan Redeye Biomedical Inc. hold?
Taiwan Redeye Biomedical Inc. holds 15 US granted patents filed between 2020 and 2024, spanning 12 technology areas.
What is Taiwan Redeye Biomedical Inc.'s Innovation Score?
Taiwan Redeye Biomedical Inc. has an Innovation Score of 48.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Taiwan Redeye Biomedical Inc. focus on?
Taiwan Redeye Biomedical Inc.'s top technology area is G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES) with 14 patents. The company has filed patents in 12 CPC subclasses total.
Is Taiwan Redeye Biomedical Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Taiwan Redeye Biomedical Inc..
What does claim depth mean for Taiwan Redeye Biomedical Inc.'s patents?
Taiwan Redeye Biomedical Inc.'s patents average 13.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the Taiwan Redeye Biomedical Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Taiwan's 15 grants land it in the top 17% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Taiwan ranks #19,252 of 50,000. Top 50 holders
- Most of this portfolio concentrates in G01N - see who else leads that technology area. G01N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
G01N technology
Taiwan Redeye Biomedical Inc.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Taiwan Redeye Biomedical Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.